Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
THORAZINE (chlorpromazine) is an oral tablet small-molecule antipsychotic approved in 1957 as a pioneering first-generation agent. The exact indications are not fully specified in available data, but historically it has been used for psychotic disorders and severe behavioral disturbances. It works primarily through dopamine antagonism in the central nervous system.
As a decades-old agent approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on cost management and niche positioning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked open positions and approaching loss of exclusivity, THORAZINE offers limited career growth; roles that do exist focus on managing the product's decline and transition to generic. Assignment to this product is typically a maintenance role, not a launchpad for advancement.
Worked on THORAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.